Compare Match Group Inc (MTCH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Sana Biotechnology Inc — how do they compare? Match Group Inc trades at $36.82 (market cap $8.45B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Match Group Inc is far larger — about 7.5× Sana Biotechnology Inc's market cap, and Match Group Inc pays a 2.17% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MTCH | SANA | |
|---|---|---|
Market Cap | $8.45B | $1.13B |
Sector | Media | Health |
52-Week High | $41.24 | $5.92 |
52-Week Low | $28.90 | $2.68 |
Enterprise Value | $11.42B | $1.05B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Match Group (MTCH) trades at $36.63, down 0.27% with bearish technical signals despite reasonable valuation metrics (P/E 13.05, P/S 2.66). Recent Q2 2026 earnings missed revenue estimates with $853 million (down 1% YoY) though Tinder engagement improved and Hinge grew 22% YoY. Operating cash flow remains strong at $1.08 billion in 2025, but high debt ($3.85 billion) and negative shareholder equity pose balance sheet concerns.
The outlook is mixed: analyst consensus is Buy (53% of 32 analysts) with $42.33 price target (16% upside), but near-term revenue pressure and Tinder's sluggish performance create headwinds. Investment opportunity lies in Hinge's international expansion and Tinder turnaround potential, while risks include execution missteps, competitive threats, and macroeconomic sensitivity affecting dating app usage.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
